Evogene (NASDAQ:EVGN – Get Free Report) is expected to announce its Q3 2026 results before the market opens on Thursday, November 19th. Analysts expect the company to announce earnings of ($0.19) per share and revenue of $0.36 million for the quarter. Investors can find conference call details on the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, November 19, 2026 at 9:00 AM ET.
Evogene Stock Up 6.3%
Evogene stock opened at $0.40 on Thursday. The firm’s 50 day simple moving average is $0.42 and its 200 day simple moving average is $0.64. Evogene has a 1-year low of $0.25 and a 1-year high of $1.28.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Evogene in a research report on Friday, October 2nd. One investment analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, the company presently has a consensus rating of “Sell”.
Evogene Company Profile
Evogene Ltd. (NASDAQ: EVGN) is an Israel-based computational biology company that develops technologies and products designed to improve human health, agriculture and sustainability. The company uses artificial intelligence, machine learning and biological data analysis through its Computational Predictive Biology platform to identify and develop solutions based on biological mechanisms. Evogene has built a portfolio of subsidiaries and business units focused on areas including agricultural biologicals, crop protection, microbiome-based therapeutics and medical cannabis.
Featured Stories
- Five stocks we like better than Evogene
- Keeping AI Cool: AAON Rides the AI Heatwave to Record Growth
- AST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn’t Going Away
- Powering Up the Moon: Redwire’s $40 Million NASA Award
- Can Constellation Energy’s Contracts Power a Stock Rebound?
Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with MarketBeat.com's FREE daily email newsletter.
